ArticleHigh blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension2026
Lack of regional and whole body sympathetic normalization during antihypertensive drug treatment: a potential link for the residual risk.
Article in High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neuroimmune regulation of post-traumatic bone regeneration: focus on inflammatory switching and functional recovery.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIt is unknown whether the failure of antihypertensive drug treatment to normalize sympathetic cardiovascular (CV) function reported in previous studies selectively affects regional sympathetic CV outflow or it also involves whole body neuroadrenergic drive.
aimThe present study examines the impact of antihypertensive drug treatment on regional and whole body sympathetic CV influences.
methodsFifthyfour essential hypertensive patients were included in the study. In each patient measurements consisted of the microneurographic recording of muscle sympathetic nerve traffic (MSNA) and the assay of venous plasma norepinephrine (NE). They were performed before and during an antihypertensive drug treatment (monotherapy or two-drugs combination) prolonged for a 3 months period. Measurements were also carried out in 31 age-matched normotensive controls.
resultsIn the study population antihypertensive drug treatment lowered clinic blood pressure to values <140/90 mmHg and significantly (P<0.001) reduced both MSNA and NE. However, during treatment the values of these two adrenergic markers remained significantly greater (+70.8 % and +64.4%, respectively) than those detected in the normotensive subjects.
conclusionsThese data provide evidence that antihypertensive drug treatment reduces but not normalizes regional and whole body sympathetic CV drive, likely participating at determining the residual CV risk reported in different studies in treated hypertensives.
Indexed as
Identifiers
41849137What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.